Treatment of Residual Refraction Errors 6 Months After Trifocal IOL Implantation With Relex-Smile
Succesful Treatment of Residual Refraction Errors (Myopic and Hyperopic) 6 Months After Trifocal IOL Implantation With Relex-Smile
1 other identifier
interventional
130
1 country
1
Brief Summary
Successful treatment of residual refraction 6 months after IOL Implantation with Relex-Smile.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Jun 2016
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2018
CompletedFirst Submitted
Initial submission to the registry
January 13, 2021
CompletedFirst Posted
Study publicly available on registry
January 15, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2026
ExpectedAugust 27, 2024
August 1, 2024
2 years
January 13, 2021
August 26, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
Increase of visual acuity
Increase of visual acuity by reducing residual refractive errors (myopia, hyperopia) using ReLex Smile after Trifocal IOL implantation
6 months
Study Arms (2)
ReLex Smile surgery
OTHERThe aim of this study is to investigate the effect of Relex Smile surgery to correct the residual refractive errors (myopic and hyperopic) 6 months after Trifocal IOL Implantation. At myopic residual refraction (min -0.75 D) (100eyes) 6 months after Trifocal IOL Implantation we used Relex-Smile surgery for treatment.
ReLex Smile surgery-fresh corneal lenticule implantation
OTHERAt hyperopic residual refraction 30 eyes 6 months after Trifocal IOL Implantation we used fresh corneal myopic lenticule implantation as allogenic implant that will be taken from myopic patients to implant on pseudophakic patients with residual hypermetropic refraction using VisuMax Femtosecond Laser-Smile module surgery with primary objective to assess(increase) visual acuity.
Interventions
Procedure/Surgery: Relex Smile The residual myopic refraction on Pseudophakic patients after 6 months using Relex-Smile surgery by VisuMax femtosecond laser. The residual refractive power was min -0.75D.The optical zone (lenticule diameter) and cap diameter were 6.5 and 7.5 mm respectively. After dissection of both anterior and posterior planes, the lenticule was extracted through 120 degree superior 3.5 mm incision and marked with a sterile marker(ViscotMedster).
VisuMax femtosecond laser performed flap-cut procedure with an energy cut index of 30 nJ (150nJ), spot and track spacing surface cut of 4.5 μm, side cut 2.0 μm were used to create an intrastromal pocket into the patient's cornea to receive the donor lenticule. The stromal pocket diameter was set 7.6 to 8.0 mm (1 mm larger than the optical zone of the donor lenticule) and cap thickness was set to 130 μm from corneal surface and a 4 mm superior incision. Hinge position flap was set at 90°, angle 50° and width 4 mm, side cut angle 90°. The pocket was dissected using a blunt spatula washed with normal saline. The lenticule was held with lenticule forceps and gently inserted into the pocket through the 4 mm superior incision. In pseudophakic patients with hyperopic astigmatism residual refraction, corneal topography-guided intrastromal fresh lenticular implantation should be performed according to the low K values.
Eligibility Criteria
You may qualify if:
- residual hypermetropic, myopic refraction on pseudophakic patients
- low visual acuity
You may not qualify if:
- active anterior segment pathologic features,
- previous corneal or anterior segment surgery,
- glaucoma,
- retinal detachment
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Eye Hospital Pristina
Pristina, 10000, Kosovo
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Head of Ophthalmology Department
Study Record Dates
First Submitted
January 13, 2021
First Posted
January 15, 2021
Study Start
June 1, 2016
Primary Completion
June 1, 2018
Study Completion (Estimated)
June 1, 2026
Last Updated
August 27, 2024
Record last verified: 2024-08